GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Retained Earnings

HURA (TuHURA Biosciences) Retained Earnings : $-162.05 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. TuHURA Biosciences's retained earnings for the quarter that ended in Sep. 2024 was $-162.05 Mil.

TuHURA Biosciences's quarterly retained earnings declined from Mar. 2024 ($-93.32 Mil) to Jun. 2024 ($-98.58 Mil) and declined from Jun. 2024 ($-98.58 Mil) to Sep. 2024 ($-162.05 Mil).

TuHURA Biosciences's annual retained earnings declined from Dec. 2021 ($-49.48 Mil) to Dec. 2022 ($-59.16 Mil) and declined from Dec. 2022 ($-59.16 Mil) to Dec. 2023 ($-88.48 Mil).


TuHURA Biosciences Retained Earnings Historical Data

The historical data trend for TuHURA Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Retained Earnings Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Retained Earnings
-49.48 -59.16 -88.48

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial -77.87 -88.48 -93.32 -98.58 -162.05

TuHURA Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


TuHURA Biosciences  (NAS:HURA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


TuHURA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.